Marina Biotech makes organisational changes

Creates the position of executive vice president of r&d

Marina Biotech, a US nucleic acid-based drug discovery and development firm, has made some organisational changes.

Richard Ho has joined the firm in the newly created position of executive vice president, Research and Development.

In addition, Philip Ranker has become interim chief financial officer, replacing Peter Garcia who has resigned from the role to pursue other opportunities.

Barry Polisky has moved from chief scientific officer to distinguished scientist and has become chairman of the firm's Scientific Advisory Panel and Michael Templin has been promoted to the newly created position of senior vice president and chief technology officer.

Finally, Alan Dunton has joined the firm as consulting chief medical officer.

Marina Biotech’s goal is to improve human health through the development of RNAi and RNA-based compounds and drug delivery technologies.

You may also like

Research & Development

Drug licensing deals in 2010

Big pharma companies have been busy filling the yawning gaps in their product pipelines by licensing drugs developed by smaller biotechnology firms. Dr Sarah Houlton outlines a selection of the deals done this year
Research & Development

Marina Biotech acquires RNA assets of Novosom

Buys patent rights to Smarticles technology
Research & Development

CAR T-cell therapy shows promise for restoring gut health and intestinal regeneration

Researchers at Cold Spring Harbor Laboratory have demonstrated that anti-uPAR CAR T-cell therapy can clear senescent cells and restore intestinal regeneration, offering a potential new approach to treating age- and radiation-related gut damage
Research & Development

New Osaka-developed reverse genetics system accelerates norovirus vaccine and drug research

Osaka University scientists have created the first simple, efficient system to generate infectious human noroviruses, paving the way for faster antiviral screening and vaccine development
Research & Development

Chemify secures $1.6m Gates Foundation grant to accelerate digital chemistry for tuberculosis drug discovery

The follow-on funding supports Chemify and Lgenia in designing and synthesising new small-molecule candidates for high-priority TB targets using Chemify’s AI-driven digital chemistry platform
Research & Development

GlaxoSmithKline and Oxford BioTherapeutics partner to advance antibody-based therapeutics for cancer

The collaboration leverages OBT's proprietary OGAP-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets
Research & Development

PLL Therapeutics opens New Zealand subsidiary to accelerate ALS clinical research in Asia-Pacific

The new entity will support Phase II ALS patient recruitment in New Zealand (where incidence rates exceed the global average) and expand PLL Therapeutics’ footprint in the Asia-Pacific neurodegenerative disease research landscape
Subscribe now